Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage
Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage
Status: Enrolling
Updated:  10/20/2015
University of Cincinnati
mi
from
Cincinnati, OH
Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage
Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage
Status: Enrolling
Updated: 10/20/2015
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Long QT Syndrome-Population Genetics and Cardiac Studies
Long QT Syndrome-Population Genetics and Cardiac Studies
Status: Enrolling
Updated:  10/20/2015
University of Rochester
mi
from
Rochester, NY
Long QT Syndrome-Population Genetics and Cardiac Studies
Long QT Syndrome-Population Genetics and Cardiac Studies
Status: Enrolling
Updated: 10/20/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol
CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol
Status: Enrolling
Updated:  10/20/2015
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol
CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol
Status: Enrolling
Updated: 10/20/2015
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
Cardiology PC
mi
from
Birmingham, AL
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
Cardiology PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
Duke University Hospital
mi
from
Durham, NC
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
Florida Hospital - Pepin Heart Institute
mi
from
Tampa, FL
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
Florida Hospital - Pepin Heart Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
Scripps Clinic - Torrey Pines, Scripps Green Hospital
mi
from
La Jolla, CA
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
Scripps Clinic - Torrey Pines, Scripps Green Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
Texas Heart Institute
mi
from
Houston, TX
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
Texas Heart Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
University of Florida
mi
from
Gainesville, FL
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated:  10/21/2015
University of Utah Health Care
mi
from
Salt Lake City, UT
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.
Status: Enrolling
Updated: 10/21/2015
University of Utah Health Care
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II
Status: Enrolling
Updated:  10/21/2015
University Hospital Case Medical Center
mi
from
Cleveland, OH
Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)
Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II
Status: Enrolling
Updated: 10/21/2015
University Hospital Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease
Status: Enrolling
Updated:  10/23/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease
Status: Enrolling
Updated: 10/23/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])
Increasing Activity in Peripheral Arterial Disease
Status: Enrolling
Updated:  10/27/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])
Increasing Activity in Peripheral Arterial Disease
Status: Enrolling
Updated: 10/27/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety & Health Improvement: Enhancing Law Enforcement Departments
Safety & Health Improvement: Enhancing Law Enforcement Departments
Status: Enrolling
Updated:  10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Safety & Health Improvement: Enhancing Law Enforcement Departments
Safety & Health Improvement: Enhancing Law Enforcement Departments
Status: Enrolling
Updated: 10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Personalized Dashboard to Educate Veterans at Risk of Stroke
A Personalized Dashboard to Educate Veterans at Risk of Stroke
Status: Enrolling
Updated:  10/28/2015
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
A Personalized Dashboard to Educate Veterans at Risk of Stroke
A Personalized Dashboard to Educate Veterans at Risk of Stroke
Status: Enrolling
Updated: 10/28/2015
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
Status: Enrolling
Updated:  10/28/2015
Retina Consultants of Houston/The Medical Center
mi
from
Houston, TX
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
Status: Enrolling
Updated: 10/28/2015
Retina Consultants of Houston/The Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
Status: Enrolling
Updated:  10/28/2015
Retina Consultants of Houston
mi
from
Katy, TX
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
Status: Enrolling
Updated: 10/28/2015
Retina Consultants of Houston
mi
from
Katy, TX
Click here to add this to my saved trials
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
Status: Enrolling
Updated:  10/28/2015
Retina Consultants of Houston
mi
from
The Woodlands, TX
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.
Status: Enrolling
Updated: 10/28/2015
Retina Consultants of Houston
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Examining Psychosocial Mediators of Exercise Behavior
Examining Psychosocial Mediators of Exercise Behavior
Status: Enrolling
Updated:  10/28/2015
HealthPartners Research Foundation
mi
from
Minneapolis, MN
Examining Psychosocial Mediators of Exercise Behavior
Examining Psychosocial Mediators of Exercise Behavior
Status: Enrolling
Updated: 10/28/2015
HealthPartners Research Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)
Targeting Systemic Inflammation to Concurrently Treat Late-Life Depression and Reduce Coronary Artery Disease Risk
Status: Enrolling
Updated:  10/30/2015
Indiana University-Purdue University Indianapolis (IUPUI)
mi
from
Indianapolis, IN
Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)
Targeting Systemic Inflammation to Concurrently Treat Late-Life Depression and Reduce Coronary Artery Disease Risk
Status: Enrolling
Updated: 10/30/2015
Indiana University-Purdue University Indianapolis (IUPUI)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
A Trial of Inhaled Nitric Oxide (NO) as an Anti-Inflammatory and Anti-Reperfusion Agent in the Treatment of Infants and Children Undergoing Cardiopulmonary Bypass for Repair of Congenital Heart Disease
Status: Enrolling
Updated:  11/3/2015
St. Louis Children's Hospital
mi
from
St. Louis, MO
Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
A Trial of Inhaled Nitric Oxide (NO) as an Anti-Inflammatory and Anti-Reperfusion Agent in the Treatment of Infants and Children Undergoing Cardiopulmonary Bypass for Repair of Congenital Heart Disease
Status: Enrolling
Updated: 11/3/2015
St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography
Lexi-Echo - a Rapid, Portable, Non-radiating Diagnostic Test for Myocardial Ischemia That is Accurate Relative to Simultaneously Obtained Nuclear SPECT MPI
Status: Enrolling
Updated:  11/3/2015
University of Arizona Medical Center
mi
from
Tucson, AZ
Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography
Lexi-Echo - a Rapid, Portable, Non-radiating Diagnostic Test for Myocardial Ischemia That is Accurate Relative to Simultaneously Obtained Nuclear SPECT MPI
Status: Enrolling
Updated: 11/3/2015
University of Arizona Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy
Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy
Status: Enrolling
Updated:  11/4/2015
Texas A&M University
mi
from
College Station, TX
Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy
Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy
Status: Enrolling
Updated: 11/4/2015
Texas A&M University
mi
from
College Station, TX
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Southeast Clinical Research, Llc
mi
from
Chiefland, FL
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Southeast Clinical Research, Llc
mi
from
Chiefland, FL
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Jacksonville Center For Clinical Research - Univ Campus
mi
from
Jacksonville, FL
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Jacksonville Center For Clinical Research - Univ Campus
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Florida Cardiovascular Institute
mi
from
Tampa, FL
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Florida Cardiovascular Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Phillip D. Toth, Md
mi
from
Indianapolis, IN
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Phillip D. Toth, Md
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
L-MARC Research Center
mi
from
Louisville, KY
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
L-MARC Research Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Commonwealth Biomedical Research, LLC
mi
from
Madisonville, KY
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Commonwealth Biomedical Research, LLC
mi
from
Madisonville, KY
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Mgh Cardiac Mr Pet Ct Program
mi
from
Boston, MA
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Mgh Cardiac Mr Pet Ct Program
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Troy Internal Medince Pc/Research
mi
from
Troy, MI
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Troy Internal Medince Pc/Research
mi
from
Troy, MI
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Radiant Research, Inc.
mi
from
Edina, MN
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Radiant Research, Inc.
mi
from
Edina, MN
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Mount Sinai School Of Medicine Imaging Science Laboratories
mi
from
New York, NY
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Mount Sinai School Of Medicine Imaging Science Laboratories
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
The Lipid Center
mi
from
Statesville, NC
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
The Lipid Center
mi
from
Statesville, NC
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Sterling Research Group
mi
from
Cincinnati, OH
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Radiant Research, Inc.
mi
from
Dallas, TX
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Radiant Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Baylor College of Medicine
mi
from
Houston, TX
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Mcallen Heart Clinic
mi
from
Mc Allen, TX
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Mcallen Heart Clinic
mi
from
Mc Allen, TX
Click here to add this to my saved trials
Improving Patient Access to Stroke Therapy Study
Improving Patient Access to Stroke Therapy Study
Status: Enrolling
Updated:  11/6/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Improving Patient Access to Stroke Therapy Study
Improving Patient Access to Stroke Therapy Study
Status: Enrolling
Updated: 11/6/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effect of Valsartan on Carotid Artery Disease
Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)
Status: Enrolling
Updated:  11/9/2015
Emory University School of Medicine
mi
from
Atlanta, GA
Effect of Valsartan on Carotid Artery Disease
Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)
Status: Enrolling
Updated: 11/9/2015
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University of Colorado Denver
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University of Colorado Hospital
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University Hospital, the University of Colorado Health Sciences Center
mi
from
Denver, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University Hospital, the University of Colorado Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study
Status: Enrolling
Updated:  11/10/2015
University of Florida
mi
from
Jacksonville, FL
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study
Status: Enrolling
Updated: 11/10/2015
University of Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor Mediated Signaling in Ticagrelor Treated Patients
Status: Enrolling
Updated:  11/10/2015
Dominick Angiolillo
mi
from
Jacksonville, FL
In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor Mediated Signaling in Ticagrelor Treated Patients
Status: Enrolling
Updated: 11/10/2015
Dominick Angiolillo
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Modified Stem Cells in Stable Ischemic Stroke
A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
A Study of Modified Stem Cells in Stable Ischemic Stroke
A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials